

B H Ebdrup

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3636107/publications.pdf>

Version: 2024-02-01

45
papers

1,077
citations

430874

18
h-index

434195

31
g-index

49
all docs

49
docs citations

49
times ranked

1807
citing authors

#	ARTICLE	IF	CITATIONS
1	Hippocampal and caudate volume reductions in antipsychotic-naive first-episode schizophrenia. <i>Journal of Psychiatry and Neuroscience</i> , 2010, 35, 95-104.	2.4	103
2	Progressive striatal and hippocampal volume loss in initially antipsychotic-naive, first-episode schizophrenia patients treated with quetiapine: relationship to dose and symptoms. <i>International Journal of Neuropsychopharmacology</i> , 2011, 14, 69-82.	2.1	78
3	Volumetric Changes in the Basal Ganglia After Antipsychotic Monotherapy: A Systematic Review. <i>Current Medicinal Chemistry</i> , 2013, 20, 438-447.	2.4	74
4	Glucagon-like peptide-1 receptor agonists for antipsychotic-associated cardio-metabolic risk factors: A systematic review and individual participant data meta-analysis. <i>Diabetes, Obesity and Metabolism</i> , 2019, 21, 293-302.	4.4	69
5	Striatal Reward Activity and Antipsychotic-Associated Weight Change in Patients With Schizophrenia Undergoing Initial Treatment. <i>JAMA Psychiatry</i> , 2016, 73, 121.	11.0	68
6	Adverse cardiac events in outpatients initiating clozapine treatment: a nationwide register-based study. <i>Acta Psychiatrica Scandinavica</i> , 2018, 137, 47-53.	4.5	54
7	Effect of GLP-1 receptor agonist treatment on body weight in obese antipsychotic-treated patients with schizophrenia: a randomized, placebo-controlled trial. <i>Diabetes, Obesity and Metabolism</i> , 2017, 19, 162-171.	4.4	53
8	Frontal fasciculi and psychotic symptoms in antipsychotic-naive patients with schizophrenia before and after 6 weeks of selective dopamine D2/3 receptor blockade. <i>Journal of Psychiatry and Neuroscience</i> , 2016, 41, 133-141.	2.4	44
9	The influence of impaired processing speed on cognition in first-episode antipsychotic-naïve schizophrenic patients. <i>European Psychiatry</i> , 2013, 28, 332-339.	0.2	38
10	No cognitive-enhancing effect of GLP-1 receptor agonism in antipsychotic-treated, obese patients with schizophrenia. <i>Acta Psychiatrica Scandinavica</i> , 2017, 136, 52-62.	4.5	36
11	Two subgroups of antipsychotic-naive, first-episode schizophrenia patients identified with a Gaussian mixture model on cognition and electrophysiology. <i>Translational Psychiatry</i> , 2017, 7, e1087-e1087.	4.8	32
12	Patterns of white matter microstructure in individuals at ultra-high-risk for psychosis: associations to level of functioning and clinical symptoms. <i>Psychological Medicine</i> , 2017, 47, 2689-2707.	4.5	32
13	Glucagon-like peptide-1 analogs against antipsychotic-induced weight gain: potential physiological benefits. <i>BMC Medicine</i> , 2012, 10, 92.	5.5	24
14	A machine-learning framework for robust and reliable prediction of short- and long-term treatment response in initially antipsychotic-naïve schizophrenia patients based on multimodal neuropsychiatric data. <i>Translational Psychiatry</i> , 2020, 10, 276.	4.8	24
15	White matter maturation during 12 months in individuals at ultra-high-risk for psychosis. <i>Acta Psychiatrica Scandinavica</i> , 2018, 137, 65-78.	4.5	23
16	Widespread higher fractional anisotropy associates to better cognitive functions in individuals at ultra-high risk for psychosis. <i>Human Brain Mapping</i> , 2019, 40, 5185-5201.	3.6	22
17	Sustained Weight Loss After Treatment With a Glucagon-Like Peptide-1 Receptor Agonist in an Obese Patient With Schizophrenia and Type 2 Diabetes. <i>American Journal of Psychiatry</i> , 2013, 170, 681-682.	7.2	21
18	Treatment of antipsychotic-associated obesity with a GLP-1 receptor agonist protocol for an investigator-initiated prospective, randomised, placebo-controlled, double-blinded intervention study: the TAO study protocol. <i>BMJ Open</i> , 2014, 4, e004158.	1.9	20

#	ARTICLE	IF	CITATIONS
19	Accuracy of diagnostic classification algorithms using cognitive-, electrophysiological-, and neuroanatomical data in antipsychotic-naïve schizophrenia patients. <i>Psychological Medicine</i> , 2019, 49, 2754-2763.	4.5	20
20	Associations between P3a and P3b amplitudes and cognition in antipsychotic-naïve first-episode schizophrenia patients. <i>Psychological Medicine</i> , 2019, 49, 868-875.	4.5	18
21	Differential effects of age at illness onset on verbal memory functions in antipsychotic-naïve schizophrenia patients aged 12–43 years. <i>Psychological Medicine</i> , 2021, 51, 1570-1580.	4.5	17
22	Selective attention and mismatch negativity in antipsychotic-naïve, first-episode schizophrenia patients before and after 6 months of antipsychotic monotherapy. <i>Psychological Medicine</i> , 2017, 47, 2155-2165.	4.5	16
23	Striatal Volume Increase After Six Weeks of Selective Dopamine D2/3 Receptor Blockade in First-Episode, Antipsychotic-Naïve Schizophrenia Patients. <i>Frontiers in Neuroscience</i> , 2020, 14, 484.	2.8	15
24	Associations between cortical thickness and auditory verbal hallucinations in patients with schizophrenia: A systematic review. <i>Psychiatry Research - Neuroimaging</i> , 2018, 282, 31-39.	1.8	13
25	Sexual dysfunction and hyperprolactinemia in schizophrenia before and after six weeks of D2/3 receptor blockade – An exploratory study. <i>Psychiatry Research</i> , 2019, 274, 58-65.	3.3	13
26	Patterns of Cortical Structures and Cognition in Antipsychotic-Naïve Patients With First-Episode Schizophrenia: A Partial Least Squares Correlation Analysis. <i>Biological Psychiatry: Cognitive Neuroscience and Neuroimaging</i> , 2019, 4, 444-453.	1.5	12
27	Bone Status in Obese, Non-diabetic, Antipsychotic-Treated Patients, and Effects of the Glucagon-Like Peptide-1 Receptor Agonist Exenatide on Bone Turnover Markers and Bone Mineral Density. <i>Frontiers in Psychiatry</i> , 2018, 9, 781.	2.6	11
28	Agents intervening against delirium in the intensive care unit (AID-ICU) – Protocol for a randomised placebo-controlled trial of haloperidol in patients with delirium in the ICU. <i>Acta Anaesthesiologica Scandinavica</i> , 2019, 63, 1426-1433.	1.6	10
29	No Effects of Cognitive Remediation on Cerebral White Matter in Individuals at Ultra-High Risk for Psychosis – A Randomized Clinical Trial. <i>Frontiers in Psychiatry</i> , 2020, 11, 873.	2.6	9
30	A new genetic locus for antipsychotic-induced weight gain: A genome-wide study of first-episode psychosis patients using amisulpride (from the OPTiMiSE cohort). <i>Journal of Psychopharmacology</i> , 2020, 34, 524-531.	4.0	9
31	Global fractional anisotropy predicts transition to psychosis after 12 months in individuals at ultra-high risk for psychosis. <i>Acta Psychiatrica Scandinavica</i> , 2021, 144, 448-463.	4.5	9
32	Postprandial prolactin suppression appears absent in antipsychotic-treated male patients. <i>Psychoneuroendocrinology</i> , 2015, 60, 1-6.	2.7	8
33	The impact of schizophrenia and intelligence on the relationship between age and brain volume. <i>Schizophrenia Research: Cognition</i> , 2019, 15, 1-6.	1.3	8
34	Identification of a Serotonin 2A Receptor Subtype of Schizophrenia Spectrum Disorders With Pimavanserin: The Sub-Sero Proof-of-Concept Trial Protocol. <i>Frontiers in Pharmacology</i> , 2020, 11, 591.	3.5	8
35	The Agents Intervening against Delirium in the Intensive Care Unit Trial (AID-ICU trial): A detailed statistical analysis plan. <i>Acta Anaesthesiologica Scandinavica</i> , 2020, 64, 1357-1364.	1.6	7
36	Phenotypic factors associated with amisulpride-induced weight gain in first-episode psychosis patients (from the OPTiMiSE cohort). <i>Acta Psychiatrica Scandinavica</i> , 2019, 140, 283-290.	4.5	6

#	ARTICLE	IF	CITATIONS
37	Multimodal assessment of white matter microstructure in antipsychotic-naïve schizophrenia patients and confounding effects of recreational drug use. <i>Brain Imaging and Behavior</i> , 2021, 15, 36-48.	2.1	6
38	Increased use of coercive procedures and prolonged hospitalization in compulsory admitted psychotic patients, who refuse antipsychotic medication. <i>Nordic Journal of Psychiatry</i> , 2020, 74, 323-326.	1.3	5
39	Associations between cognition and white matter microstructure in first-episode antipsychotic-naïve patients with schizophrenia and healthy controls: A multivariate pattern analysis. <i>Cortex</i> , 2021, 139, 282-297.	2.4	5
40	Extrastriatal dopamine D2/3 receptors and cortical grey matter volumes in antipsychotic-naïve schizophrenia patients before and after initial antipsychotic treatment. <i>World Journal of Biological Psychiatry</i> , 2017, 18, 539-549.	2.6	4
41	Heritability of Memory Functions and Related Brain Volumes: A Schizophrenia Spectrum Study of 214 Twins. <i>Schizophrenia Bulletin Open</i> , 2020, 1, .	1.7	3
42	Weight gain on antipsychotics – A perfect storm of complex pathophysiology and psychopharmacology. <i>Acta Psychiatrica Scandinavica</i> , 2021, 144, 521-523.	4.5	3
43	Volumetric Changes in the Basal Ganglia After Antipsychotic Monotherapy: A Systematic Review. <i>Current Medicinal Chemistry</i> , 2013, 20, 438-447.	2.4	2
44	Gamma-hydroxybutyric acid-induced organic delirium complicated by polydrug use successfully treated with electroconvulsive therapy: a case report. <i>Journal of Medical Case Reports</i> , 2021, 15, 596.	0.8	2
45	“No cognitive-enhancing effect of <sc>GLP</sc> receptor agonism in antipsychotic-treated, obese patients with schizophrenia”: authors' response. <i>Acta Psychiatrica Scandinavica</i> , 2017, 136, 526-527.	4.5	0